SCHEMBL6419670

SCHEMBL6419670

CC(C)(C)NC(=O)c1cc(F)ccc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.56
APEX1 P27695 1/20 0.56
CES2 O00748 3/20 0.55
CES1 P23141 3/20 0.55
ALOX5AP P20292 2/20 0.51
FEN1 P39748 2/20 0.51
ANO1 Q5XXA6 2/20 0.48
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
TAS1R2 Q8TE23 1/20 0.47
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HTT P42858 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
CTDSP1 Q9GZU7 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PSMB11 A5LHX3 1/20 0.42
PSMA7 O14818 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419619 0.86 POLB (0.56) POLBAPEX1CES2CES1ALOX5AP
SCHEMBL6419790 0.83 CNR2 (0.51) POLBAPEX1CES2CES1ANO1
SCHEMBL13377324 0.83 POLB (0.53) POLBAPEX1ALOX5APFEN1ANO1
SCHEMBL15915661 0.83 POLB (0.49) POLBAPEX1CES2CES1ALOX5AP
SCHEMBL4333053 0.83 KEAP1 (0.56) POLBAPEX1ALOX5APFEN1ANO1
SCHEMBL24799394 0.81 ANO1 (0.54) POLBAPEX1ALOX5APFEN1ANO1
SCHEMBL4599072 0.81 POLB (0.50) POLBAPEX1CES2CES1ALOX5AP
SCHEMBL14484567 0.80 POLB (0.50) POLBAPEX1ALOX5APFEN1ANO1
SCHEMBL20812767 0.80 POLB (0.50) POLBAPEX1ANO1KDM4EALDH1A1
SCHEMBL6415787 0.79 POLB (0.71) POLBAPEX1ALOX5APFEN1ANO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936736-B2 Amide derivative SUMITOMO MANUFACTURING COMPANY LIMITED (JP) 2005-08-30 US disclosed
EP-1034783-B1 AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS SUMITOMO PHARMA (JP) 2004-12-15 EP disclosed
US-20020147204-A1 Amide derivative SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2002-10-10 US disclosed
US-6384033-B1 DRUGS FOR VISION DEFECTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-05-07 US disclosed
EP-1034783-A1 AMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2000-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147204-A1 Amide derivative ALDH1A2, NR1H2, HDAC3 POLB 3216/4885APEX1 1777/4885CES2 3713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.